['hypoglycemia']
['biod-961', 'lilly glucagon', 'novo glucagon']

        Inclusion Criteria:

          -  Body Mass Index: 18.5-25.0 kg/m2 inclusive.

          -  Subject has provided informed consent and has signed and dated an informed consent
             form before any trial-related activities.

        Exclusion Criteria:

          -  Type 1 or type 2 diabetes mellitus.

          -  History of pheochromocytoma, insulinoma, glucagonoma, or glycogen storage disease.

          -  History of regular alcohol consumption as defined by alcohol intake exceeding 7 drinks
             per week for females or 14 drinks per week for males, where 1 drink = 5 ounces of wine
             or 12 ounces of beer or 1.5 ounces of hard liquor.

          -  Significant cardiovascular (to include New York Heart Association (NYHA) Class III or-
             IV functional capacity or uncontrolled hypertension), respiratory, gastrointestinal,
             hepatic, renal, neurological, psychiatric and/or hematological disease.

          -  Any significant cardiovascular event history, including angina, myocardial infarction,
             therapeutic coronary procedure (e.g, percutaneous transluminal coronary angioplasty,
             coronary bypass surgery), stroke, or transient ischemic attack.

          -  Females who are breast feeding, pregnant, or intending to become pregnant during the
             study.
      